The USC Norris Comprehensive Cancer Center, in collaboration with Auransa Inc., is about to begin a phase 1 clinical trial to evaluate the efficacy of a new medical treatment for cancers of the liver. In pre-clinical trials, the drug has been shown to interrupt the machinery of cancer cells, preventing them from using DNA code to produce the proteins that they need to multiply.
Liver cancer is estimated to be the third most common cause of cancer-related deaths worldwide, and hepatocellular carcinoma (HCC) accounts for about 80% of all liver cancers. Despite major improvements in treatment, patients with advanced HCC continue to have limited median overall survival due to primary or secondary resistance to existing therapies.
To read the full story, click here.